A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT00276094 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

826

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrophy
Vaginal Diseases

Interventions

DRUG: Ospemifene 30 mg
DRUG: Ospemifene 60 mg
DRUG: Placebo
DRUG: Nonhormonal vaginal lubricant

Sponsor

Shionogi

Collaborators

[object Object]
[object Object]